Filing Analysis
Regulation FD Disclosure
Filed Apr 30, 2026
LOW
Cartesian Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished with the SEC filing.
Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The announcement was made on April 30, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Carsten Brunn, Ph.D., serves as the President, CEO, and Chairman of the Board.
Officer Departure
Filed Mar 30, 2026
LOW
Dr. Murat Kalayoglu notified Cartesian Therapeutics of his resignation from the Board of Directors, effective March 31, 2026. He served as the Chairman of the Science and Technology Committee and his departure is reportedly not due to any disagreements with the company.
Key Facts
- Dr. Murat Kalayoglu resigned from the Board of Directors effective March 31, 2026.
- Kalayoglu served as Chairman of the Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee.
- The company stated the resignation was to 'pursue other opportunities' and not the result of any disagreement regarding operations, policies, or practices.
- Dr. Kalayoglu had served on the Board since 2023.
Regulation FD Disclosure
Filed Mar 09, 2026
LOW
Cartesian Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The filing serves as a standard disclosure to furnish the earnings press release to the SEC.
Key Facts
- The company reported financial results for the full year ended December 31, 2025, on March 9, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The information provided is furnished and not considered 'filed' for purposes of Section 18 of the Exchange Act.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.